31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

Where Big Pharma is betting big in the M&A boom

29 July 2026 Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?

MedTech

Boston Scientific overturns $42m patent verdict on appeal

28 July 2026 Years of litigation over biodegradable drug-delivery technology took another turn after the Federal Circuit delivered a significant win for the medical device maker.

Regulation & Industry

Buying the brains: Why is Big Pharma shopping for innovation?

27 July 2026 With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?

More features

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

‘Blatant imitation’: Indian court blocks copycat pharma branding

Kirkland & Ellis adds leading barrister in London

Kilpatrick adds tech patent litigator and China expert to Chicago office

Litigator from Brown Rudnick moves firms to chair practice

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features